BCTXZ — BriaCell Therapeutics Corp. Warrant
NASDAQ · Healthcare · Biotechnology
$0.12
+$0.01 (+4.55%)
BriaCell Therapeutics Corp. Warrant (BCTXZ) is a biotechnology company listed on NASDAQ. It is led by William V. Williams FCPA, M.D., based in Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1. BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Net income was -$26.6M.
Use this BCTXZ page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BCTXZ quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BCTXZ SEC filings page. Lician reads the product cache first so this HTML stays unique to BriaCell Therapeutics Corp. Warrant even when a live quote feed is slow.
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
BCTXZ Key Statistics
Market Cap
$0.00M
Volume
20,349
Previous Close
$0.11
Day Range
$0.11 – $0.13
EPS
-$62.19
Revenue
$0.00
Net Income
-$26.56M
Gross Profit
$0.00
Free Cash Flow
$0.00
BCTXZ Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$26.56M | -$4.93M | -$20.30M | -$26.84M |
| EPS (Diluted) | -$62.19 | -$43.68 | -$1.30 | -$1.73 |
Total Assets
$21.65M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$10.49M
Operating Cash Flow
-$28.17M
Free Cash Flow
$0.00
BriaCell Therapeutics Corp. Warrant Company Information
- CEO, President & Director
- William V. Williams FCPA, M.D.
- Headquarters
- Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
- Website
- briacell.com
- Phone
- 604-921-1810
- IPO / Founded
- 2025-04-25
- Sector
- Healthcare
- Industry
- Biotechnology